{"id":2764,"company":{"country":"US","currency":"USD","exchange":"NASDAQ NMS - GLOBAL MARKET","ipo":"2023-01-20","marketCap":21.87820053100586,"name":"Cadrenal Therapeutics Inc","phone":"19043000701","outstanding":13.020000457763672,"symbol":"CVKD","website":"https://www.cadrenal.com/","industry":"Pharmaceuticals"},"price":1.6275,"year":2024,"month":1,"day":31,"weekday":"Wednesday","title":"Impact of Currency Fluctuations on Cadrenal Therapeutics Inc","date":"2024-01-31","url":"/posts/2024/01/31/CVKD","content":[{"section":"Currency Risk","text":"Currency risk refers to the potential impact of exchange rate fluctuations on the financial performance of multinational companies. Cadrenal Therapeutics Inc, being a multinational stock, is exposed to currency risk due to its operations in different countries. Fluctuations in currency exchange rates can significantly impact the company's financial results."},{"section":"Positive Impact","text":"In certain cases, currency fluctuations may have a positive impact on Cadrenal Therapeutics Inc. For instance, if the company generates a significant portion of its revenues in a foreign currency that appreciates against the Canadian dollar, it can benefit when converted back to its home currency. This can lead to increased revenues and profitability."},{"section":"Negative Impact","text":"On the other hand, currency fluctuations can also have a negative impact on Cadrenal Therapeutics Inc. If the company has significant foreign currency expenses or debt, a depreciating home currency can increase its costs, reducing profitability. Additionally, currency volatility can create uncertainty and make it challenging for the company to plan and forecast its financials accurately."},{"section":"Case Study 1: Cadrenal Therapeutics Inc and the Strong US Dollar","text":"In 2015, Cadrenal Therapeutics Inc, a Canadian pharmaceutical company, experienced a negative impact from the strengthening of the US dollar. The company exported a significant portion of its products to the United States, and the strengthening US dollar made its products more expensive for US customers, leading to a decline in sales and profitability."},{"section":"Case Study 2: Cadrenal Therapeutics Inc and the Weakening Euro","text":"In contrast, when the Euro weakened in 2018, Cadrenal Therapeutics Inc benefited as it had a manufacturing facility in Germany. The weakened Euro made its products cheaper for customers in other countries which use the Euro as their currency. This resulted in increased demand for Cadrenal Therapeutics Inc products and consequently higher revenues and profitability."},{"section":"Opportunities and Risks","text":"Currency fluctuations present both opportunities and risks for Cadrenal Therapeutics Inc. While unexpected currency movements can pose risks to the company's financial performance, they can also create opportunities for increased competitiveness. For example, a depreciating currency can make the company's products more affordable for foreign customers, potentially leading to market expansion and increased market share."},{"section":"Conclusion","text":"Currency fluctuations can have a significant impact on Cadrenal Therapeutics Inc's multinational stock. While they can create both positive and negative effects on the company's revenues and expenses, they also present opportunities for increased competitiveness and market expansion. Balancing and managing currency risk is crucial for the company's financial stability and growth."}],"tags":["CrossOver21","Long","Pharmaceuticals"],"news":[{"category":"company","date":1706610124,"headline":"Here's Why We're Not Too Worried About Cadrenal Therapeutics' (NASDAQ:CVKD) Cash Burn Situation","id":125400932,"image":"https://media.zenfs.com/en/simply_wall_st__316/fd5474a7eee0c5f442903b68fe63249b","symbol":"CVKD","publisher":"Yahoo","summary":"There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...","url":"https://finance.yahoo.com/news/heres-why-were-not-too-102204874.html"},{"category":"company","date":1706513460,"headline":"ZIM, ACET and LUNR are among pre market gainers","id":125377963,"image":"","symbol":"CVKD","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3322207133"},{"category":"company","date":1706252640,"headline":"Why Tellurian Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket","id":125328654,"image":"","symbol":"CVKD","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3318614554"},{"category":"company","date":1706104800,"headline":"Cadrenal Therapeutics to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024","id":125289242,"image":"https://media.zenfs.com/en/prnewswire.com/9a3c37d0d610e035cdba8fe0d711428b","symbol":"CVKD","publisher":"Yahoo","summary":"Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes and deaths due to blood clots in patients with certain conditions, announced today that Douglas Losordo, M.D., Chief Medical Officer of Cadrenal, will participate in a fireside chat moderated by Joe Pantginis, Ph.D., Managing Director of Research at H.C. Wainwright \u0026 Co., at the Lytham Partn","url":"https://finance.yahoo.com/news/cadrenal-therapeutics-participate-fireside-chat-140000147.html"},{"category":"company","date":1706080500,"headline":"Why Netflix Shares Are Trading Higher By 10%; Here Are 20 Stocks Moving Premarket","id":125274398,"image":"","symbol":"CVKD","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3314713008"},{"category":"company","date":1705894500,"headline":"12 Health Care Stocks Moving In Monday's After-Market Session","id":125229679,"image":"","symbol":"CVKD","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3311734414"},{"category":"company","date":1705744800,"headline":"Stocks To Watch: Eyes On Chipmakers, Tesla, Netflix And BrightSpring IPO","id":125194543,"image":"https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png","symbol":"CVKD","publisher":"SeekingAlpha","summary":"Stay informed of the latest market events with Seeking Alpha's Stocks to Watch.","url":"https://seekingalpha.com/article/4663833-stocks-to-watch-eyes-on-chipmakers-tesla-netflix-and-brightspring-ipo"},{"category":"company","date":1705579980,"headline":"Why KeyCorp Shares Are Trading Lower By Over 5%? Here Are Other Stocks Moving In Thursday's Mid-Day Session","id":125137542,"image":"","symbol":"CVKD","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3306227151"},{"category":"company","date":1705560960,"headline":"Why M.D.C. Holdings Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket","id":125137938,"image":"","symbol":"CVKD","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3305843627"}]}